Vlasveld, L T <br/><br/>
Treatment of low-grade non-Hodgkin's lymphoma with continuous infusion of low-dose recombinant interleukin-2 in combination with the B-cell-specific monoclonal antibody CLB-CD19.  [electronic resource] 

 -  Cancer immunology, immunotherapy : CII  Jan 1995 
 - 37-47 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0340-7004 
<br/><br/><label>Standard No.: </label>10.1007/BF01517234  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Animals<br/>Antibodies, Monoclonal--adverse effects<br/>Antigen-Antibody Reactions<br/>Antigens, CD--immunology<br/>Antigens, CD19<br/>Antigens, Differentiation, B-Lymphocyte--immunology<br/>B-Lymphocytes--immunology<br/>Combined Modality Therapy<br/>Complement System Proteins--metabolism<br/>Cytotoxicity, Immunologic<br/>Dose-Response Relationship, Immunologic<br/>Female<br/>Humans<br/>Immunoglobulins--blood<br/>Immunophenotyping<br/>Infusions, Intravenous<br/>Interleukin-2--adverse effects<br/>Leukocyte Count<br/>Lymphocyte Activation<br/>Lymphoma, Non-Hodgkin--immunology<br/>Male<br/>Mice<br/>Middle Aged<br/>Receptors, Interleukin-2--metabolism<br/>Recombinant Proteins--therapeutic use<br/>T-Lymphocytes--immunology